M. O. Karlsson

Irinotecan pathway genotype analysis to predict pharmacokinetics (2003)

Mathijssen, R.H., Marsh, S., Karlsson, M.O., Xie, R., Baker, S.D., Verweij, J., ...

PURPOSE: The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of...

Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria

Sidhu, J S, Ashton, M, Huong, N V, Hai, T N, Karlsson, M O, Sy, N D, ...

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients

Hassan, M, Svensson, U S H, Ljungman, P, Björkstrand, B, Olsson, H, Bielenstein, M, ...

Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of Pharmacokinetics and Pharmacodynamics

Rydberg *, T., Jönsson, A., Karlsson, M. O., Melander, A.

Aims The main purpose of this paper is to describe the relationship between serum concentrations of glibenclamide and its main metabolites and the effects on blood glucose levels, the clinically...

Developmental pharmacokinetics of ciclosporin – a population pharmacokinetic study in paediatric renal transplant candidates

Fanta, S, Jönsson, S, Backman, J T, Karlsson, M O, Hoppu, K

What is already known about this subjectCiclosporin is an immunosuppressant drug with a narrow therapeutic index and large variability in pharmacokinetics.It is likely that the inter- and...